VIA Pharmaceuticals Announces Strategic Restructuring and Financing

VIA Pharmaceuticals Announces Strategic Restructuring and Financing

Financing, Workforce Reduction Aimed at Focusing Resources on Research and Development Related to Pipeline Drug Candidates

SAN FRANCISCO, CA, Mar 31, 2010 (MARKETWIRE via COMTEX News Network) -- VIA Pharmaceuticals, Inc. (PINKSHEETS: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced a strategic restructuring and financing aimed at focusing the Company's resources on research and development related to its pipeline of drug candidates. The Company announced a $1.25 million draw from a new $3.0 million secured Note and Warrant Purchase Agreement with the Company's principal stockholder. Details of the agreement, its terms and conditions are described in the Company's 2009 annual report filed with the Securities and Exchange Commission on form 10-K today. The Company also announced that it will reduce its workforce to a core research and development team.

"VIA's pipeline takes a novel approach to the treatment of major cardiovascular and metabolic diseases, including atherosclerosis and diabetes," said Lawrence K. Cohen, Ph.D., Chief Executive Officer of VIA Pharmaceuticals. By focusing our workforce on a core research and development team and raising this new financing, we have provided additional time to explore opportunities for advancing these promising product candidates, including strategic partnerships or additional financings."

VIA's pipeline product candidates include:

--  VIA-2291, a Phase 3 ready inhibitor of 5-LO, a key enzyme for the
    production of leukotrienes, which are mediators of inflammation
    believed to be involved in the development and progression of
    atherosclerosis. No therapy currently exists to directly target
    inflammation in plaque, a potential catalyst for heart attack, stroke
    and other acute coronary events
--  VIA-3196, an IND ready thyroid hormone receptor (THR) beta agonist for
    the control of cholesterol, triglyceride levels and potential in
    insulin sensitization/diabetes
--  A preclinical diacylglycerol acyl transferase 1 (DGAT1) metabolic
    disorders program

Dr. Cohen added, "While this new financing provides resources to allow us to continue pursuing our goals while we seek additional capital, we regret that the reduction in force affects a number of our employees, whom I want to personally thank for their loyalty and hard work."

The Company's reduction in force primarily affects finance and business development personnel. The reduction which is effective March 31, 2010 reduces the total number of employees at the Company by approximately 63%, to a total of six employees.

About VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in plaque, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: http://www.viapharmaceuticals.com.

Forward Looking Statements This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

--  our ability to find a market maker to apply and be cleared by the
    Financial Industry Regulatory Authority to quote our common stock on
    the OTC Bulletin Board;
--  ability and willingness of active market makers in our common stock to
    trade our common stock on the Pink Sheets under a "piggyback
    qualification";
--  our ability to borrow additional amounts under the new loan from Bay
    City Capital, which is subject to the discretion of Bay City Capital;
--  our ability to obtain necessary financing in the near term, including
    amounts necessary to repay the previous loan from Bay City Capital
    following the April 1, 2010 maturity date;
--  our ability to control our operating expenses;
--  our ability to comply with covenants included in the loans from Bay
    City Capital;
--  our ability to operate following the implementation of our strategic
    restructuring;
--  our ability to comply with SEC reporting obligations following our
    strategic restructuring;
--  our ability to timely recruit and enroll patients in any future
    clinical trials;
--  our failure to obtain sufficient data from enrolled patients that can
    be used to evaluate VIA-2291, thereby impairing the validity or
    statistical significance of our clinical trials;
--  our ability to successfully complete our clinical trials of VIA-2291
    on expected timetables and the outcomes of such clinical trials;
--  complexities in designing and implementing cardiometabolic clinical
    trials using surrogate endpoints in Phase 1 and Phase 2 clinical
    trials which may differ from the ultimate endpoints required for
    registration of a candidate drug;
--  the results of our clinical trials, including without limitation, with
    respect to the safety and efficacy of VIA-2291;
--  if the results of the ACS and CEA studies, upon further review and
    analysis, are revised, interpreted differently by regulatory
    authorities or negated by later stage clinical trials;
--  our ability to obtain necessary FDA approvals, including to initiate
    future clinical trials of VIA-2291;
--  our ability to successfully commercialize VIA-2291;
--  our ability to identify potential clinical candidates from the family
    of DGAT1 compounds licensed and move them into preclinical
    development;
--  our ability to obtain and protect our intellectual property related to
    our product candidates;
--  our potential for future growth and the development of our product
    pipeline, including the THR beta agonist candidate and the other
    compounds licensed from Roche;
--  our ability to obtain strategic opportunities to partner and
    collaborate with large biotechnology or pharmaceutical companies to
    further develop VIA-2291;
--  our ability to form and maintain collaborative relationships to
    develop and commercialize our product candidates;
--  general economic and business conditions; and the other risks
    described under Item IA "Risk Factors" in our Annual Report on Form
    10-K for the fiscal year ended December 31, 2009 on file with the SEC.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA undertakes no obligation to update publicly any of these statements in light of new information or future events.

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.